ライフサイエンスコーパス: sustained ventricular tachycardia

1 The most common adverse event (n=6) was sustained ventricular tachycardia.

2 ventricular fibrillation, or polymorphic or sustained ventricular tachycardia.

3 ained ventricular tachycardia, and inducible sustained ventricular tachycardia.

4 f healing canine infarcts were mapped during sustained ventricular tachycardia.

5 are independently associated with inducible sustained ventricular tachycardia.

6 en patients with and those without inducible sustained ventricular tachycardia.

7 coronary artery disease will have inducible sustained ventricular tachycardia.

8 uns of nonsustained ventricular tachycardia, sustained ventricular tachycardia, aborted sudden cardia

9 duced pause-dependent ventricular ectopy and sustained ventricular tachycardia after acute myocardial

10 is a noninvasive marker of the substrate of sustained ventricular tachycardia after myocardial infar

11 2)-adrenergic receptor blocker and developed sustained ventricular tachycardia after transverse aorti

12 f successful ablation sites in patients with sustained ventricular tachycardia and coronary artery di

13 s without arrhythmias; however, they develop sustained ventricular tachycardia and sudden cardiac dea

14 shock, nonfatal ventricular fibrillation, or sustained ventricular tachycardia); and a composite of H

15 , 5 patients died suddenly, 9 had documented sustained ventricular tachycardia, and another 5 had app

16 AACEs included postdischarge sudden death, sustained ventricular tachycardia, and ventricular fibri

17 eath in patients with hemodynamically stable sustained ventricular tachycardia complicating coronary

18 All susceptible dogs had spontaneous sustained ventricular tachycardia culminating in SCD.

19 left ventricular dysfunction, and inducible sustained ventricular tachycardia during electrophysiolo

20 -/-) mice vs. 0/10 Kcne3(+/+) mice exhibited sustained ventricular tachycardia during reperfusion (P<

21 ally unique manner to those who present with sustained ventricular tachycardia (e.g., adenosine-sensi

22 tricular conduction abnormalities, inducible sustained ventricular tachycardia, enrollment as an inpa

23 receiving the ICD previously had documented sustained ventricular tachycardia/fibrillation or cardia

24 the following events: sudden cardiac death, sustained ventricular tachycardia/fibrillation, or appro

25 rcuits in the EBZ of infarcted hearts during sustained ventricular tachycardias (>30 seconds, n=17 ep

26 as ventricular fibrillation in 157 patients, sustained ventricular tachycardia in 236, both ventricul

27 t enhancer Bay Y5959 prevented initiation of sustained ventricular tachycardia in 7 of 14 experiments

28 cations occurred in nine patients, including sustained ventricular tachycardia in five, myocardial in

29 Flecainide prevented catecholamine-induced sustained ventricular tachycardia in RyR2(R4496C+/-) mic

30 infarcts with a multielectrode array during sustained ventricular tachycardia induced by programmed

31 Sustained ventricular tachycardia induced by programmed

32 tcome of death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacema

33 nonsustained ventricular tachycardia in whom sustained ventricular tachycardia is induced.

34 There were no episodes of sustained ventricular tachycardia, myocardial infarction

35 plantable cardiac defibrillator shock (n=4), sustained ventricular tachycardia (n=1), or sudden death

36 verter defibrillator interventions (n=7), or sustained ventricular tachycardia (n=11).

37 D because of ventricular fibrillation (n=6), sustained ventricular tachycardia (n=14), and appropriat

38 All patients had documented, sustained ventricular tachycardia, no coronary artery di

39 th (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left v

40 ventricular ectopic beats, nonsustained and sustained ventricular tachycardia of left bundle branch

41 le sex (P < .0001), presenting arrhythmia of sustained ventricular tachycardia or fibrillation (P < .

42 The incidence and timing of sustained ventricular tachycardia or fibrillation (VT/VF

43 elevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard

44 s during P2, and suppressed the incidence of sustained ventricular tachycardia or ventricular fibrill

45 r death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrill

46 ariate predictors for arrhythmic end points (sustained ventricular tachycardia or ventricular fibrill

47 defibrillator to treat an initial episode of sustained ventricular tachycardia or ventricular fibrill

48 In patients with histories of sustained ventricular tachycardia or ventricular fibrill

49 For patients resuscitated from sustained ventricular tachycardia or ventricular fibrill

50 For patients who have not had sustained ventricular tachycardia or ventricular fibrill

51 den cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or arrhythmogenic syn

52 defined as sudden cardiac death, documented sustained ventricular tachycardia, or non-fatal cardiac

53 nce of nonsustained ventricular tachycardia, sustained ventricular tachycardia, or supraventricular t

54 orphic ventricular ectopy (in the absence of sustained ventricular tachycardia) originating from the

55 fatal episode of ventricular fibrillation or sustained ventricular tachycardia requiring external car

56 ath/life-threatening ventricular arrhythmia (sustained ventricular tachycardia, resuscitated sudden c

57 me (composite measure of first occurrence of sustained ventricular tachycardia/resuscitated sudden ca

58 or their ability to abolish pace-induced and sustained ventricular tachycardia (SVT) or prevent induc

59 tely 5% of patients with PVCs have inducible sustained ventricular tachycardia that behaves in an ide

60 econdary prevention (after cardiac arrest or sustained ventricular tachycardia), the devices were act

61 primary end point was sudden cardiac death, sustained ventricular tachycardia, ventricular fibrillat

62 However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillati

63 esigned to assess the predictive accuracy of sustained ventricular tachycardia/ventricular fibrillati

64 for death in early follow-up (0-3 hrs after sustained ventricular tachycardia/ventricular fibrillati

65 as to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillati

66 ist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillati

67 h acute myocardial infarction complicated by sustained ventricular tachycardia/ventricular fibrillati

68 r arrhythmia (resuscitated cardiac arrest or sustained ventricular tachycardia/ventricular fibrillati

69 for life-threatening arrhythmias, defined as sustained ventricular tachycardia (VT) >/=240 beats/min

70 The de novo occurrence of sustained ventricular tachycardia (VT) after CABG has be

71 Sustained ventricular tachycardia (VT) and fibrillation

72 Sustained ventricular tachycardia (VT) and sudden cardia

73 al activity contributes to the initiation of sustained ventricular tachycardia (VT) as reflected in i

74 Sustained ventricular tachycardia (VT) can be unstable,

75 lectrophysiologic testing revealed inducible sustained ventricular tachycardia (VT) in six of the eig

76 ngation (> or = 180 ms) is a risk marker for sustained ventricular tachycardia (VT) late after repair

77 Reported shocks were confirmed for sustained ventricular tachycardia (VT) or fibrillation (

78 ction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fi

79 g and radiofrequency ablation of postinfarct sustained ventricular tachycardia (VT) remain one of the

80 thetic nerve activity (SNA) increases during sustained ventricular tachycardia (VT), and the magnitud

81 rhythmic death, resuscitated cardiac arrest, sustained ventricular tachycardia (VT), and torsade de p

82 is discovered on the rate of inducibility of sustained ventricular tachycardia (VT), arrhythmic event

83 Adverse events (AE)-death or sustained ventricular tachycardia (VT)-were ascertained

84 patients (n = 32) with clinically documented sustained ventricular tachycardia (VT).

85 was defined as sudden cardiac death (SCD) or sustained ventricular tachycardia (VT)/ventricular fibri

86 ) sudden cardiac arrest; 2) nonsustained and sustained ventricular tachycardia (VT); 3) pre-excitatio

87 objective of this study was to determine why sustained ventricular tachycardias (VT) sometimes stop w

88 To determine the mechanisms of resetting, sustained ventricular tachycardia was induced in dogs wi

89 Sustained ventricular tachycardia was more likely to be

90 The rate of inducibility of sustained ventricular tachycardia was significantly high

91 atal ventricular fibrillation and those with sustained ventricular tachycardia with syncope or systol

92 substrate of sudden death resembled that of sustained ventricular tachycardia, with pulmonary regurg